PL2991633T3 - Terapia bakteriofagami - Google Patents

Terapia bakteriofagami

Info

Publication number
PL2991633T3
PL2991633T3 PL14724663T PL14724663T PL2991633T3 PL 2991633 T3 PL2991633 T3 PL 2991633T3 PL 14724663 T PL14724663 T PL 14724663T PL 14724663 T PL14724663 T PL 14724663T PL 2991633 T3 PL2991633 T3 PL 2991633T3
Authority
PL
Poland
Prior art keywords
bacteriophagy
therapy
bacteriophagy therapy
Prior art date
Application number
PL14724663T
Other languages
English (en)
Inventor
Pascal Danglas
Laurent Debarbieux
Original Assignee
Ferring Bv
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv, Pasteur Institut filed Critical Ferring Bv
Publication of PL2991633T3 publication Critical patent/PL2991633T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL14724663T 2013-04-30 2014-04-30 Terapia bakteriofagami PL2991633T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13305568.1A EP2799063A1 (en) 2013-04-30 2013-04-30 Bacteriophage therapy
PCT/EP2014/058840 WO2014177622A1 (en) 2013-04-30 2014-04-30 Bacteriophage therapy
EP14724663.1A EP2991633B1 (en) 2013-04-30 2014-04-30 Bacteriophage therapy

Publications (1)

Publication Number Publication Date
PL2991633T3 true PL2991633T3 (pl) 2019-10-31

Family

ID=48485088

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14724663T PL2991633T3 (pl) 2013-04-30 2014-04-30 Terapia bakteriofagami
PL19172749T PL3563837T3 (pl) 2013-04-30 2014-04-30 Terapia bakteriofagami

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL19172749T PL3563837T3 (pl) 2013-04-30 2014-04-30 Terapia bakteriofagami

Country Status (28)

Country Link
US (3) US11040078B2 (pl)
EP (3) EP2799063A1 (pl)
JP (1) JP6543615B2 (pl)
KR (1) KR102215453B1 (pl)
CN (1) CN105407872B (pl)
AU (1) AU2014261461B2 (pl)
BR (1) BR112015027269B1 (pl)
CA (1) CA2910539C (pl)
DK (2) DK2991633T3 (pl)
EA (1) EA034195B1 (pl)
ES (2) ES2740124T3 (pl)
HR (2) HRP20211860T2 (pl)
HU (2) HUE056968T2 (pl)
IL (1) IL242293B (pl)
LT (2) LT3563837T (pl)
MX (1) MX366497B (pl)
MY (1) MY186607A (pl)
NZ (1) NZ713423A (pl)
PH (1) PH12015502500A1 (pl)
PL (2) PL2991633T3 (pl)
PT (2) PT2991633T (pl)
RS (2) RS59046B1 (pl)
SA (1) SA515370073B1 (pl)
SG (1) SG11201508897QA (pl)
SI (2) SI2991633T1 (pl)
TR (1) TR201910955T4 (pl)
WO (1) WO2014177622A1 (pl)
ZA (1) ZA201508212B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2799063A1 (en) 2013-04-30 2014-11-05 Ferring B.V. Bacteriophage therapy
CA3051867A1 (en) * 2017-03-14 2018-09-20 Brigham Young University Methods and compositions for treating obesity, inflammation, or metabolic disorders with bacteriophages
JP2020533408A (ja) * 2017-09-08 2020-11-19 学校法人慶應義塾 炎症性腸疾患を制御するためのバクテリオファージ
US11986502B2 (en) 2018-05-23 2024-05-21 Optium, LLC Bacteriophage compositions and kits and related methods
CA3101242A1 (en) * 2018-05-23 2019-11-28 Brigham Young University Bacteriophage compositions and kits and related methods
AU2020415391B2 (en) * 2019-12-23 2025-10-23 Entasis Therapeutics, Inc. Managing microbial dysbiosis with temocillin
US20220323517A1 (en) * 2021-04-10 2022-10-13 Intron Biotechnology, Inc. Compositions and methods for inhibiting the proliferation of enterotoxigenic bacteroides fragilis
US20220331381A1 (en) * 2021-04-10 2022-10-20 Intron Biotechnology, Inc. Compositions and methods for inhibiting the proliferation of enterotoxigenic bacteroides fragilis
US20220323518A1 (en) * 2021-04-10 2022-10-13 Intron Biotechnology, Inc. Compositions and methods for inhibiting the proliferation of enterotoxigenic bacteroides fragilis
KR20230173188A (ko) 2021-04-22 2023-12-26 훼링 비.브이. 부착-침습성 대장균에 대한 박테리오파지 치료법
US20250160335A1 (en) * 2023-11-16 2025-05-22 The United States Of America, As Represented By The Secretary Of Agriculture Formulation of a lytic bacteriophage cocktail for biocontrol of shiga toxin-producing escherichia coli strains

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020013270A1 (en) * 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
GB0019721D0 (en) * 2000-08-10 2000-09-27 Regma Biotechnologies Ltd Novel method
EP2377883A1 (en) 2010-04-15 2011-10-19 Universite d'Auvergne Clermont I Antagonists for the prevention or treatment of inflammatory bowel disease, and more particularly of Crohn's disease
EP3443970B1 (en) * 2010-09-17 2020-09-09 Tecnifar-Indústria Técnica Farmacêutica, S.A. Antibacterial phage, phage peptides and methods of use thereof
WO2013045863A1 (fr) 2011-09-29 2013-04-04 Institut Pasteur Detection de souches e.coli de serotype o104
EP2799063A1 (en) 2013-04-30 2014-11-05 Ferring B.V. Bacteriophage therapy

Also Published As

Publication number Publication date
SA515370073B1 (ar) 2018-02-12
HRP20211860T2 (hr) 2022-03-18
SI2991633T1 (sl) 2019-09-30
HK1221164A1 (en) 2017-05-26
DK3563837T3 (da) 2021-12-06
LT3563837T (lt) 2021-12-27
PT3563837T (pt) 2021-12-03
HUE056968T2 (hu) 2022-04-28
BR112015027269B1 (pt) 2023-04-25
DK2991633T3 (da) 2019-07-29
SI3563837T1 (sl) 2022-04-29
RS59046B1 (sr) 2019-08-30
AU2014261461B2 (en) 2019-04-18
RS62644B1 (sr) 2021-12-31
HRP20211860T1 (hr) 2022-03-04
US11040078B2 (en) 2021-06-22
KR20160005728A (ko) 2016-01-15
EP3563837B9 (en) 2022-02-16
PH12015502500B1 (en) 2016-02-22
DK3563837T5 (da) 2022-03-21
EA201591979A1 (ru) 2016-04-29
ZA201508212B (en) 2022-03-30
JP6543615B2 (ja) 2019-07-10
JP2016519126A (ja) 2016-06-30
US20160143965A1 (en) 2016-05-26
LT2991633T (lt) 2019-07-25
SG11201508897QA (en) 2015-11-27
EP3563837B1 (en) 2021-10-20
HUE044431T2 (hu) 2019-10-28
US12478652B2 (en) 2025-11-25
BR112015027269A2 (pt) 2017-09-26
EA034195B1 (ru) 2020-01-16
PH12015502500A1 (en) 2016-02-22
WO2014177622A1 (en) 2014-11-06
US20210386805A1 (en) 2021-12-16
EP2991633B1 (en) 2019-06-19
US11918613B2 (en) 2024-03-05
CN105407872B (zh) 2020-06-12
MX2015015092A (es) 2016-06-07
US20240342230A1 (en) 2024-10-17
AU2014261461A1 (en) 2015-11-12
RS62644B9 (sr) 2022-04-29
CN105407872A (zh) 2016-03-16
EP2799063A1 (en) 2014-11-05
PL3563837T3 (pl) 2022-02-07
CA2910539C (en) 2022-05-17
IL242293B (en) 2019-09-26
CA2910539A1 (en) 2014-11-06
MY186607A (en) 2021-07-30
PT2991633T (pt) 2019-08-07
HRP20191363T1 (hr) 2019-11-01
NZ713423A (en) 2020-07-31
EP2991633A1 (en) 2016-03-09
ES2740124T3 (es) 2020-02-05
ES2902599T3 (es) 2022-03-29
MX366497B (es) 2019-07-11
KR102215453B1 (ko) 2021-02-15
TR201910955T4 (tr) 2019-08-21
EP3563837A1 (en) 2019-11-06

Similar Documents

Publication Publication Date Title
NL301252I2 (nl) tislelizumab
NO2023037I1 (no) Mirikizumab
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
HRP20181334T1 (hr) Samohodno plovilo
HUE037097T2 (hu) Hõszigetelõpanel
DK3077047T3 (da) Aramcholsalte
DK3052081T3 (da) Pastil
DK3060460T3 (da) Saddel
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK2956698T5 (da) Bindestrimler
PL3563837T3 (pl) Terapia bakteriofagami
EP2943489A4 (en) DEUTERATED MOMELOTINIB
DK2946640T3 (da) Langmuir-probe
DE102013106534B8 (de) Chromatographiepipettenspitze
EP2970310A4 (en) 5-BROMO-indirubins
EP2853297A4 (en) kendama
DK3071227T3 (da) Fiskevaccine
DE112014001252A5 (de) Aufbissschiene
DK3086679T3 (da) Sportssko
DK2981168T3 (da) Laminitiskile
FI20136034A7 (fi) Sauna
FI10138U1 (fi) Kelkkateltta
ES1078715Y (es) Mosquitera
UA28711S (uk) Масажер